Exploring the therapeutic impact of Salvia officinalis on lipid and oxidative stress markers in patients with polycystic ovary syndrome – a randomized placebo-controlled clinical trial DOI Creative Commons
Arezoo Maleki‐Hajiagha, Faraz Mojab, Fardin Amidi

et al.

BMC Complementary Medicine and Therapies, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 26, 2025

Salvia.officinalis (S. officinalis), is recognized for its antihyperlipidemic, metabolism-regulating, and antioxidant properties in diabetic hyperlipidemic disorders. This study examining effects on lipid oxidative stress (OS) markers patients with Polycystic Ovary Syndrome (PCOS), thereby substantiating role managing metabolic In this randomized placebo-controlled trial was performed gynecology clinics affiliated to Iran University of Medical Sciences. Accordingly, 70 Iranian married women aged 15–40 years newly diagnosed PCOS were included. They receive either 330 mg S. officinalis extract or placebo daily eight weeks. The outcomes included profile OS markers. found a significantly lower triglyceride levels malondialdehyde after weeks intake compared placebo. Also, the mean change triglyceride, high-density lipoprotein cholesterol, malondialdehyde, total capacity statistically significant intervention group. demonstrates that can reduce PCOS, suggesting potential as an adjunctive natural therapy imbalances associated condition. While did not alter other markers, observed improvements highlight therapeutic promise officinalis. These findings support further investigation into clinical applications benefits health. IRCT201504146917N2 2015–10-03 (registered while recruiting).

Language: Английский

Exploring the Anti-Colon Cancer Potential of Polygonum minus: Integrating In Vitro and In Silico Studies DOI
Zhongming Yang, Zhongguo Yang,

Md Zuki Abu Bakar

et al.

Food Bioscience, Journal Year: 2025, Volume and Issue: 64, P. 105853 - 105853

Published: Jan. 6, 2025

Language: Английский

Citations

3
Exploring the therapeutic impact of Salvia officinalis on lipid and oxidative stress markers in patients with polycystic ovary syndrome – a randomized placebo-controlled clinical trial DOI Creative Commons
Arezoo Maleki‐Hajiagha, Faraz Mojab, Fardin Amidi

et al.

BMC Complementary Medicine and Therapies, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 26, 2025

Salvia.officinalis (S. officinalis), is recognized for its antihyperlipidemic, metabolism-regulating, and antioxidant properties in diabetic hyperlipidemic disorders. This study examining effects on lipid oxidative stress (OS) markers patients with Polycystic Ovary Syndrome (PCOS), thereby substantiating role managing metabolic In this randomized placebo-controlled trial was performed gynecology clinics affiliated to Iran University of Medical Sciences. Accordingly, 70 Iranian married women aged 15–40 years newly diagnosed PCOS were included. They receive either 330 mg S. officinalis extract or placebo daily eight weeks. The outcomes included profile OS markers. found a significantly lower triglyceride levels malondialdehyde after weeks intake compared placebo. Also, the mean change triglyceride, high-density lipoprotein cholesterol, malondialdehyde, total capacity statistically significant intervention group. demonstrates that can reduce PCOS, suggesting potential as an adjunctive natural therapy imbalances associated condition. While did not alter other markers, observed improvements highlight therapeutic promise officinalis. These findings support further investigation into clinical applications benefits health. IRCT201504146917N2 2015–10-03 (registered while recruiting).

Language: Английский

Citations

0